Methyldienedione
Eş anlamlı: Estra-4,9-Diene-3,17-Dione
CAS: 5173-46-6
MF: C18H22O2
MW: 270.37
tahlil: 99%
Karakter: Beyaz kristal toz.
Paketleme:Foil bag or as requirments
Kategoriler: İlaç Ara Maddeleri; Amino asitler; ara ürünler & İnce Kimyasallar; metabolitler & safsızlıklar; İlaç; steroidler
kullanım: A potential metabolitie of STS 557 (Dienogest). A steroid with antiglucocorticoid activity.
Estra-4,9-diene-3,17-dione is a powerful pro-steroid chemically similar to the anabolic agent Trenbolone.
When in the body, estra-4,9-diene-3,17-dione completes the conversion to Trenbolone. Trenbolone is a potent anabolic steroid, which binds to specific receptors present in reproductive tissue, muscle and fat.
Estra Diene Dione (estra-4,9-diene-3,17-dione) is an anabolic steroid and a precursor to Estra Diene Dione. It became a controlled substance in the US on January 4, 2010, and is classified as a Schedule III anabolic steroid under the United States Controlled Substances Act. Previous to this, it was sold as a bodybuilding supplement within the United States, and often mistakenly marketed as a prohormone for trenbolone, a veterinary steroid. Prior to its scheduling, it was part of a number of supplements that were seized during FDA enforcement for selling unapproved new drugs. The actual target steroid, Estra Diene Dione has some structural similarity to trenbolone, but lacks the 11-carbon -ene bond.
1. Protection from gynomastia,
2. Increased sex drive/libido,
3. Enhanced intensity & focus,
4. Estrogen control,
5. Positive effects on strength & lean mass.
It offers benefits such as improvements in male fertility, mood levels, shortened recovery in case of burns or severe trauma and stimulation in developing mammals. It is considered to be a more effective anti-aromatase substance than many others and is potent enough to increase testosterone levels in the body without a concomitant reduction of the estrogen levels in men. It may be used for hormone or androgen replacement therapy in men without resulting in a concomitant reduction in endogenous estrogen levels when administered in an oral or transdermal way in dosages ranging from 25-150 mg/gün.